BioLife Sciences announced the availability of the FebriDx - an ultra-rapid, disposable, point-of-care test device that identifies a clinically significant Acute Respiratory Infection (ARI) and differentiates viral from bacterial causes. Approved by Health Canada for SARS-CoV-2 (COVID-19) virus testing and other viral and bacterial infections, the test itself takes only 30 seconds and provides non-invasive test results for ARIs within ten (10) minutes. The FebriDx, available from BioLife Sciences, can be administered by trained professionals at places like: pharmacies, walk-in clinics, long-term care homes, workplaces, and doctors' offices without the need for a laboratory to determine if someone is infected with the virus. The FebriDX triage test does not replace the standard PCR test for COVID-19; however, what it does do is allow for immediate results for any bacterial and viral infections including, but not limited to, COVID-19. FebriDX testing provides accurate results within ten minutes compared with 1.7 hours with PCR testing and 24 hours with laboratory testing. Additionally, the majority of tests are currently limited to the detection of a single group of pathogens (COVID-19) and cannot distinguish between alternative viral or bacterial infections which may have similar symptoms as COVID-19.